Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical trial to date on the treatment. The highly popular drug also reduced the risk of heart disease regardless of a patient's weight, a second analysis on the same trial found. Both analyses were presented at the European Congress on Obe ...